Compare Dollar Tree, Inc. (DLTR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dollar Tree, Inc. vs Medpace Holdings Inc — how do they compare? Dollar Tree, Inc. trades at $129.5 (market cap $24.61B), while Medpace Holdings Inc trades at $598 (market cap $16.90B). The key difference: Dollar Tree, Inc. is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Dollar Tree, Inc. nearer its low. Which is the better fit depends on your goals.
| DLTR | MEDP | |
|---|---|---|
Market Cap | $24.61B | $16.90B |
Sector | Health | Technology |
52-Week High | $141.21 | $620.59 |
52-Week Low | $85.04 | $393.42 |
Enterprise Value | $31.20B | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dollar Tree (DLTR) trades at $128.85, down 0.4% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue for 2025 was $17.58 billion, but net income showed a loss of $3.03 billion due to tax impacts, while operating cash flow improved to $2.86 billion. A $2.5 billion share repurchase authorization was announced in July 2026, signaling confidence.
The outlook is mixed: analyst consensus is a Buy with a $126.69 price target, near the current price, but risks include margin pressures from tariffs and volatile profitability. Upside potential exists from cost controls and consumer demand for value, yet investors should monitor Q2 earnings and competitive dynamics closely.
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dollar Tree, Inc.
Dollar Tree operates discount stores in the U.S. and Canada, including 8,647 shops under its namesake banner and 8,016 Family Dollar units (as of the end of fiscal 2021). The eponymous chain features branded and private-label goods, generally at a $1.25 price. Around 45% of Dollar Tree stores' fiscal 2021 sales came from consumables (including food, health and beauty, and household paper and cleaning products), nearly 50% from variety items (including toys and housewares), and just over 5% from seasonal goods. Family Dollar features branded and private-label goods at prices generally ranging from $1 to $10, with over 76% of fiscal 2021 sales from consumables, 9% from seasonal/electronic items (including prepaid phones and toys), 8% from home products, and 6% from apparel and accessories.
Read more on DLTR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
